Voyager Therapeutics (NASDAQ:VYGR) Trading Down 2.8%

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares fell 2.8% during mid-day trading on Monday . The company traded as low as $8.19 and last traded at $8.19. 77,180 shares changed hands during trading, a decline of 92% from the average session volume of 940,609 shares. The stock had previously closed at $8.43.

Analysts Set New Price Targets

A number of research firms have recently issued reports on VYGR. Wells Fargo & Company raised Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. Guggenheim began coverage on Voyager Therapeutics in a research report on Tuesday, March 26th. They set a “buy” rating and a $22.00 price target on the stock. Citigroup began coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They set a “buy” rating and a $16.00 price target on the stock. HC Wainwright began coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They set a “buy” rating and a $30.00 price target on the stock. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

Voyager Therapeutics Stock Performance

The stock has a market capitalization of $433.31 million, a PE ratio of 2.58 and a beta of 0.96. The business has a 50 day moving average of $8.79 and a two-hundred day moving average of $7.95.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. The firm had revenue of $90.06 million during the quarter, compared to analysts’ expectations of $4.95 million. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. On average, equities analysts expect that Voyager Therapeutics, Inc. will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VYGR. Citigroup Inc. purchased a new stake in Voyager Therapeutics in the first quarter valued at about $186,000. BlackRock Inc. raised its stake in Voyager Therapeutics by 10.6% in the first quarter. BlackRock Inc. now owns 514,155 shares of the company’s stock valued at $3,919,000 after buying an additional 49,319 shares during the last quarter. Lazard Asset Management LLC raised its stake in Voyager Therapeutics by 144.7% in the first quarter. Lazard Asset Management LLC now owns 17,678 shares of the company’s stock valued at $134,000 after buying an additional 10,455 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in Voyager Therapeutics in the first quarter valued at about $122,000. Finally, Northern Trust Corp raised its stake in Voyager Therapeutics by 2.2% in the first quarter. Northern Trust Corp now owns 79,119 shares of the company’s stock valued at $603,000 after buying an additional 1,683 shares during the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.